Gϋnter von Minckwitz
Impact in
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
Papers in
- Oncology 267
- Cancer Treatment and Pharmacology 138
- HER2/EGFR in Cancer Research 124
- Colorectal Cancer Treatments and Studies 17
- Cancer Research 251
- Breast Cancer Treatment Studies 227
- Cancer Genomics and Diagnostics 35
- Co-authors
- Sibylle Loibl (234 shared papers)Carsten Denkert (102 shared papers)Michael Untch (133 shared papers)Manfred Kaufmann (45 shared papers)Holger Eidtmann (75 shared papers)Jens‐Uwe Blohmer (77 shared papers)Jens Huober (92 shared papers)J. Hilfrich (49 shared papers)
- Journals
- Journal of Clinical Oncology (113 papers)Annals of Oncology (46 papers)Cancer Research (38 papers)The Breast (24 papers)European Journal of Cancer (20 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Gϋnter von Minckwitz
420 papers receiving 25.0k citations
Gϋnter von Minckwitz's Hit Papers
Peers
Comparison fields: 5 of 143
- Cancer Research 10.9k
- Oncology 12.0k
- Pathology and Forensic Medicine 2.3k
- Radiology, Nuclear Medicine and Imaging 2.7k
- Pulmonary and Respiratory Medicine 2.8k
Countries citing papers authored by Gϋnter von Minckwitz
This map shows the geographic impact of Gϋnter von Minckwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gϋnter von Minckwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gϋnter von Minckwitz more than expected).
Fields of papers citing papers by Gϋnter von Minckwitz
This network shows the impact of papers produced by Gϋnter von Minckwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gϋnter von Minckwitz. The network helps show where Gϋnter von Minckwitz may publish in the future.
Co-authors
The 25 scholars most cited alongside Gϋnter von Minckwitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 431 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes Hit paper breakdown → | 2012 | 1873 |
| 2 | Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Hit paper breakdown → | 2009 | 1315 |
| 3 | Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study Hit paper breakdown → | 2013 | 951 |
| 4 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Hit paper breakdown → | 2017 | 940 |
| 5 | Molecular alterations in triple-negative breast cancer—the road to new treatment strategies Hit paper breakdown → | 2016 | 670 |
| 6 | Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update Hit paper breakdown → | 2006 | 548 |
| 7 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 537 |
| 8 | Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study Hit paper breakdown → | 2009 | 505 |
| 9 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2013 | 415 |
| 10 | 2010 | 410 | |
| 11 | 2010 | 402 | |
| 12 | 2012 | 389 | |
| 13 | 1996 | 388 | |
| 14 | 2011 | 373 | |
| 15 | 2011 | 358 | |
| 16 | 1995 | 326 | |
| 17 | 2005 | 316 | |
| 18 | 2008 | 302 | |
| 19 | 2007 | 299 | |
| 20 | 2012 | 299 |
About Gϋnter von Minckwitz
Gϋnter von Minckwitz is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Molecular Biology, having authored 431 papers that have together received 25.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (227 papers), Cancer Treatment and Pharmacology (138 papers), HER2/EGFR in Cancer Research (124 papers), Advanced Breast Cancer Therapies (77 papers), Breast Lesions and Carcinomas (38 papers), Cancer Genomics and Diagnostics (35 papers), Estrogen and related hormone effects (20 papers) and Colorectal Cancer Treatments and Studies (17 papers). The work is most often cited by research in Cancer Research (10.9k citations), Oncology (12.0k citations), Pathology and Forensic Medicine (2.3k citations), Radiology, Nuclear Medicine and Imaging (2.7k citations) and Pulmonary and Respiratory Medicine (2.8k citations). Gϋnter von Minckwitz has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Sibylle Loibl, Carsten Denkert, Michael Untch, Manfred Kaufmann, Holger Eidtmann, Jens‐Uwe Blohmer, Jens Huober, J. Hilfrich, Christian Jackisch and Serban Dan Costa. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, The Breast and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.